TxAgent, an AI agent leveraging multi-step reasoning and real-time biomedical knowledge retrieval, revolutionizes personalized drug treatment with 92.1% accuracy, outperforming leading models and ensuring treatment recommendations align with clinical guidelines to reduce adverse events.
Insilico Medicine, an AI-driven drug discovery company, raised $110 million in Series E funding to propel its AI platform Pharma.AI, advance its drug pipeline, and bolster biopharmaceutical R&D, harnessing biology, clinical data, and generative chemistry for innovative drug development.
In a groundbreaking AI breakthrough, FragFold, an innovative system leveraging AlphaFold's machine learning capabilities, accurately predicts protein fragments that can inhibit target proteins, experimentally confirming over 50% of its predictions and unlocking new frontiers in drug discovery by enabling deeper insights into protein interactions.
Evo 2, a groundbreaking AI tool, unlocks the secrets of nature's genetic code, enabling rapid protein discovery by virtually predicting the form and function of proteins encoded in the DNA of all living and extinct species, potentially revolutionizing biological research and accelerating scientific breakthroughs.